A new analysis of data from the SELECT trial shows that semaglutide, a GLP-1 receptor agonist, provides a clear cardiovascular protective effect in people with overweight or obesity and already established cardiovascular disease, even when they do not have diabetes
The precise mechanism is not yet fully understood, but may relate to: Blood sugar swings Initial lower calorie consumption Dehydration, particularly if nausea limits the consumption of fluids Many people find that headaches ease after their bodies acclimate to the medication
Ozempic is the brand name for semaglutide, and according to Gervacio, its the most popular choice since it has shown the most promise for weight loss
Because initial doses are lower, early weight loss may be modest until your optimal dose is achieved
However, 2024 clinical practice guidelineswhich were endorsed by the American Society of Anesthesiologists and several other professional medical societiesexplain that this blanket recommendation is not necessary
